(Note: IPOScoop has No Call on this small-cap unit offering. The listing here is a professional courtesy. This unit offering was upsized at pricing to 1,270,589 units, up from 1,058,824 units in the prospectus, and priced at $17 – the midpoint of its $16-to-$18 range. Each unit consists of common stock, Series A warrants and Series B warrants.)

GBS is developing and commercializing a range of Biosensor-based Point of Care (“POCT”) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Given the COVID-19 pandemic, the superior analytical characteristics of the biosensor technology and the advanced development stage, the company decided to expedite a collaboration with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss) to develop a more accurate and real-time SARS-CoV-2 test for diagnostic, point-of-care screening and pre-vaccination screening.